drugset / Trial / NCT00573495

Multipeptide Vaccine for Advanced Breast Cancer

NCT00573495 ↗

Phase 1 Completed 11 enrolled University of Pennsylvania
NaSingle-groupOpen-labelTreatment

Summary

This is a study on how to activate the immune system with a vaccine. The vaccine is made up of two proteins found in breast cancer: telomerase and survivin. The vaccine is given in combination with other drugs that may also have an effect on the immune system and attack the cancer. The goals of the study are: 1. to test the safety of the combination of agents 2. to find out what effects the treatment has on advanced breast cancer

Timeline

Start
2007-11
Primary completion
2011-07
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject hTERT/Survivin Multi-Peptide Vaccine Vaccine 100 ug Subcutaneous

Indications